Fulgent Q1 core revenue $73.5M (+16% YoY); GAAP loss $0.37/share; reiterates FY25 guidance

Fulgent Genetics, Inc.

Core revenue of $73.5M, up 16% YoY; GAAP net loss of $11.5M ($0.37 loss per share).
Non-GAAP income of $1.2M ($0.04 per share); Adjusted EBITDA loss of $2.9M.
Reiterates full-year 2025 core revenue guidance of $310M.
Cash and investments $814.6M ($26.60 per share); repurchased ~516k shares for $8.7M in Q1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.